

Starting Sept. 1, we'll change how we pay for certain medications for most Blue Cross, BCN commercial members

The table below shows the medications we won't pay for starting Sept. 1, 2025, as well as the alternative medications we'll pay for starting Sept. 1. These drugs are managed through the Oncology Value Management program, which is administered by OncoHealth.

These changes will affect most Blue Cross Blue Shield of Michigan and Blue Care Network commercial members with pharmacy benefits. These changes won't apply to Medicare Advantage groups or members.

Medications we won't pay for starting Sept. 1	Affected drug lists	Alternative medications** we'll pay for starting Sept. 1
<ul style="list-style-type: none"> Abiraterone 250 mg that's not manufactured by CivicaScript* Zytiga® 250 mg 	All	Abirtega™ (abiraterone 250 mg) manufactured by CivicaScript and filled by Walgreens Specialty Pharmacy
Imbruvica® 280 mg tablet	All	Imbruvica® 140 mg capsule (2 capsules)
<ul style="list-style-type: none"> Xalkori®*** Zykadia®*** 	All except the Custom Select Drug list (The Custom Select Drug List will be affected on Jan. 1, 2026)	<ul style="list-style-type: none"> Alecensa® Alunbrig® Lorbrena®

*Blue Cross, along with 17 other Blue plans, works with CivicaScript® (previously Civica Rx) to manufacture low-cost generic medications to reduce members' out-of-pocket costs and improve savings for our customers.

**Additional coverage requirements may apply for preferred alternatives.

***Members who have authorizations that were approved before Sept. 1 can continue to receive therapy and won't be affected by this change.

These requirements apply to the following members when they receive these drugs in an outpatient setting in Michigan or in other states:

- Blue Cross and BCN commercial members
 - All fully insured groups (group and individual), with the exception of MESSA members
 - Members who have coverage through self-funded groups that participate in the Oncology Value Management program. Refer to the document titled [Oncology Value Management program participation list for self-funded groups](#).

We'll send letters to affected groups, members and their health care providers about these changes.

How to submit prior authorization requests

Submit prior authorization requests to OncoHealth on or after Aug. 20, 2025, using one of the following methods:

- Through the OncoHealth OneUM™ portal, which you can access by logging in to our provider portal at [availity.com](https://www.availity.com),* clicking *Payer Spaces*, and then clicking the BCBSM and BCN logo. This takes you to the Blue Cross and BCN payer space where, under the *Applications* tab, you'll click the *OncoHealth Provider Portal* tile.
- By calling OncoHealth at 1-888-916-2616

[Subscribe](#) to Provider Alerts Weekly, a weekly email with a list of links to the previous week's provider alerts.

*Clicking this link means that you're leaving the Blue Cross Blue Shield of Michigan and Blue Care Network website. While we recommend this site, we're not responsible for its content.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.

OncoHealth is an independent company supporting Blue Cross Blue Shield of Michigan and Blue Care Network by providing cancer support services.

CivicaScript® is an independent company that will provide select generic drugs to Blue Cross Blue Shield of Michigan and Blue Care Network members.